FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) is an insurtech company operating in the life insurance and longevity science sector that became publicly traded after completing its business combination with CF Acquisition Corp VIII, a blank-check company sponsored by Cantor Fitzgerald, in September 2022, following the SPAC's 2021 IPO. The company developed epigenetic biomarker technology designed to modernize underwriting and risk assessment for life insurers. FOXO filed an 8-K with the SEC on May 28, 2026, bearing accession number 0001493152-26-025636, continuing its ongoing public-company reporting obligations. For the full filing history, sponsor details, and structured data on FOXO and the broader SPAC universe, sign up for SpacDesk.